Dr. Larissa A. Meyer, MD

Dr. Meyer practices at The University of Texas MD Anderson Cancer Center in Houston, Texas, part of The University of Texas System.

Dr. Meyer's NPI, 1255571568, was assigned on February 26, 2009. Dr. Meyer graduated from Harvard Medical School in 2002. Dr. Meyer holds Texas license N0976.

Dr. Meyer's primary practice is The University of Texas MD Anderson Cancer Center, at 1515 Holcombe Blvd, Houston, TX 77030.

Dr. Meyer's primary practice is The University of Texas MD Anderson Cancer Center in Houston, Texas, part of The University of Texas System. The medical group on file is Texas Children's Hospital. Dmand AI also links Dr. Meyer to 2 more medical groups, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Meyer practices. Vendor and product names are available with a free account.

Gynecologic oncology is Dr. Meyer's primary specialty in the NPI Registry, under taxonomy code 207VX0201X. Dr. Meyer is board certified in gynecologic oncology by the American Board of Obstetrics and Gynecology. Dmand AI has Dr. Meyer's licenses on file in 11 states: Texas, Florida, Arizona, Georgia, Tennessee, Louisiana, Mississippi, Washington, Alabama, Oklahoma and New York.

Dmand AI lists hysterectomy and ovarian cyst among the conditions Dr. Meyer treats.

CMS data shows 152 Medicare services from Dr. Meyer across 4 procedure codes in 2024, all of them office visits, for 112 Medicare patients. Medicare paid $15,129 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 112 Medicare patients who saw Dr. Meyer in 2024. The largest group is 65 to 74, with 63 patients. 75% of them have high blood pressure, and 67% have cancer. Their average risk score is 2.03, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Meyer's median patient age at 68, with 99% women.

In 2024, Dr. Meyer wrote 112 Medicare Part D claims for 25 patients. 59% of them were for generic drugs. CMS names the drug for 50 of them, across 3 drugs with 11 or more claims each, at $615,740 in total drug cost. In 2023, CMS named 43 claims across 3 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 84 out of 100 for Dr. Meyer for performance year 2024, reported as part of a group. Dr. Meyer accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Meyer as offering telehealth.

Removal of the uterus: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 187 papers to Dr. Meyer, published from 2008 to 2025. 2019 was the busiest year, with 20. The most frequent topics are Ovarian Neoplasms, Genital Neoplasms, Female and Gynecologic Surgical Procedures. Dr. Meyer has published most often in Gynecol Oncol. Dr. Meyer's most frequent co-authors are Karen H. Lu, MD, Pedro T. Ramirez, MD and Sharon M. Giordano, MD, MPH.

Dmand AI links Dr. Meyer to 3 clinical trials. 1 is still active or recruiting. Conditions studied include Brenner Tumor, Uterine Cervical Neoplasms and Vulvar Neoplasms. Gynecologic Oncology Group sponsors the most, 2.

CMS Open Payments shows 36 general payments to Dr. Meyer from 17 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 59% of the total. Abbvie Inc. paid the most, $4,196.

Dmand AI lists 2 awards for Dr. Meyer.

Dr. Meyer graduated from Harvard Medical School in 2002. Dr. Meyer is a member of American College of Obstetricians and Gynecologists and ACS.

Dr. Meyer is in network with 18 carriers, including Elevance, Aetna and Blue Cross Blue Shield of Michigan. PPO plans come from the most carriers, 11. Check the plan with the practice before a visit.